IRIS Accounts Production v17.3.1.106 01583708 Board of Directors 1.7.16 30.6.17 30.6.17 false true false false false false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure015837082016-06-30015837082017-06-30015837082016-07-012017-06-30015837082015-06-30015837082015-07-012016-06-30015837082016-06-3001583708ns15:EnglandWales2016-07-012017-06-3001583708ns14:PoundSterling2016-07-012017-06-3001583708ns10:Director12016-07-012017-06-3001583708ns10:PrivateLimitedCompanyLtd2016-07-012017-06-3001583708ns10:SmallEntities2016-07-012017-06-3001583708ns10:AuditExempt-NoAccountantsReport2016-07-012017-06-3001583708ns10:SmallCompaniesRegimeForDirectorsReport2016-07-012017-06-3001583708ns10:SmallCompaniesRegimeForAccounts2016-07-012017-06-3001583708ns10:AbridgedAccounts2016-07-012017-06-300158370812016-07-012017-06-3001583708ns10:Director22016-07-012017-06-3001583708ns10:CompanySecretary12016-07-012017-06-3001583708ns10:RegisteredOffice2016-07-012017-06-3001583708ns5:CurrentFinancialInstruments2017-06-3001583708ns5:CurrentFinancialInstruments2016-06-3001583708ns5:Non-currentFinancialInstruments2017-06-3001583708ns5:Non-currentFinancialInstruments2016-06-3001583708ns5:ShareCapital2017-06-3001583708ns5:ShareCapital2016-06-3001583708ns5:RevaluationReserve2017-06-3001583708ns5:RevaluationReserve2016-06-3001583708ns5:RetainedEarningsAccumulatedLosses2017-06-3001583708ns5:RetainedEarningsAccumulatedLosses2016-06-3001583708ns5:IntangibleAssetsOtherThanGoodwill2016-07-012017-06-3001583708ns5:ComputerSoftware2016-07-012017-06-3001583708ns5:PlantMachinery2016-07-012017-06-3001583708ns5:FurnitureFittings2016-07-012017-06-3001583708ns5:RevaluationReserve2016-06-3001583708ns10:Director112016-06-3001583708ns10:Director112015-06-3001583708ns10:Director112016-07-012017-06-3001583708ns10:Director112015-07-012016-06-3001583708ns10:Director112017-06-3001583708ns10:Director112016-06-3001583708ns10:Director222016-06-3001583708ns10:Director222015-06-3001583708ns10:Director222016-07-012017-06-3001583708ns10:Director222015-07-012016-06-3001583708ns10:Director222017-06-3001583708ns10:Director222016-06-30


REGISTERED NUMBER: 01583708 (England and Wales)












Unaudited Financial Statements

for the Year Ended 30 June 2017

for

Abtek (Biologicals) Limited

Abtek (Biologicals) Limited (Registered number: 01583708)






Contents of the Financial Statements
for the Year Ended 30 June 2017




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 4


Abtek (Biologicals) Limited

Company Information
for the Year Ended 30 June 2017







DIRECTORS: Mr R Turner
Mr S C Turner





SECRETARY: Mrs J M Turner





REGISTERED OFFICE: 145 Edge Lane
Liverpool
Merseyside
L7 2PG





REGISTERED NUMBER: 01583708 (England and Wales)





ACCOUNTANTS: Wilson Henry LLP
Chartered Accountants
145 Edge Lane
Liverpool
L7 2PF

Abtek (Biologicals) Limited (Registered number: 01583708)

Abridged Balance Sheet
30 June 2017

2017 2016
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 18,000 -
Tangible assets 5 52,753 58,463
70,753 58,463

CURRENT ASSETS
Stocks 71,127 93,783
Debtors 98,016 144,865
Prepayments and accrued income 5,334 10,232
Cash at bank 27,845 10,024
202,322 258,904
CREDITORS
Amounts falling due within one year 87,077 135,719
NET CURRENT ASSETS 115,245 123,185
TOTAL ASSETS LESS CURRENT
LIABILITIES

185,998

181,648

CREDITORS
Amounts falling due after more than one
year

(28,053

)

(37,381

)

PROVISIONS FOR LIABILITIES (13,040 ) (11,056 )

ACCRUALS AND DEFERRED INCOME (21,678 ) (4,650 )
NET ASSETS 123,227 128,561

CAPITAL AND RESERVES
Called up share capital 3,750 3,750
Other reserves - equity 6 10,024 10,024
Retained earnings 109,453 114,787
SHAREHOLDERS' FUNDS 123,227 128,561

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the
Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at
the end of each financial year and of its profit or loss for each financial year in accordance with the
requirements of Sections 394 and 395 and which otherwise comply with the requirements of the
Companies Act 2006 relating to financial statements, so far as applicable to the company.

Abtek (Biologicals) Limited (Registered number: 01583708)

Abridged Balance Sheet - continued
30 June 2017


The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

All the members have consented to the preparation of an abridged Statement of Income and Retained Earnings and an abridged Balance Sheet for the year ended 30 June 2017 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors on 29 March 2018 and were signed on its
behalf by:





Mr R Turner - Director


Abtek (Biologicals) Limited (Registered number: 01583708)

Notes to the Financial Statements
for the Year Ended 30 June 2017

1. STATUTORY INFORMATION

Abtek (Biologicals) Limited is a private company, limited by shares , registered in England and Wales.
The company's registered number and registered office address can be found on the Company
Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts,
rebates, value added tax and other sales taxes.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured
at cost less any accumulated amortisation and any accumulated impairment losses.

Computer software is being amortised evenly over its estimated useful life of ten years.

Amortisation begins when the intangible asset is available for use in the manner intended by
management.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 10% on cost
Fixtures and fittings - 10% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for
obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement,
except to the extent that it relates to items recognised in other comprehensive income or directly in
equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been
enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at
the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods
different from those in which they are recognised in financial statements. Deferred tax is measured
using tax rates and laws that have been enacted or substantively enacted by the year end and that are
expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable
that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Abtek (Biologicals) Limited (Registered number: 01583708)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2017

2. ACCOUNTING POLICIES - continued

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the
period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the
company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 9 (2016 - 10 ) .

4. INTANGIBLE FIXED ASSETS
Totals
£   
COST
Additions 18,000
At 30 June 2017 18,000
NET BOOK VALUE

At 30 June 2017 18,000

5. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 July 2016 204,707
Additions 3,635
At 30 June 2017 208,342
DEPRECIATION
At 1 July 2016 146,244
Charge for year 9,345
At 30 June 2017 155,589
NET BOOK VALUE
At 30 June 2017 52,753
At 30 June 2016 58,463

6. RESERVES
Other
reserves
- equity
£   
At 1 July 2016
and 30 June 2017 10,024

Abtek (Biologicals) Limited (Registered number: 01583708)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2017

7. TRANSACTIONS WITH DIRECTORS.

The Company received interest-free loans during the year. Transactions with directors subsisted
during the years ended 30 June 2017 and 30 June 2016:

2017 2016
£    £   
Mr R Turner
Balance outstanding at start of year 735 1,600
Amounts repaid (40 ) (865 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 695 735

Mr S C Turner
Balance outstanding at start of year 1,993 5,000
Amounts repaid (1,993 ) (3,007 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year - 1,993